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All activities should aim to eliminate genotoxic impurities and/or protect the API against
degradation. There is a necessity to monitor impurities from all classification groups,
hence ivabradine forced degradation studies were performed. Ivabradine was proved
to be quite durable active substance, but still new and with insufficient stability data.
Increased temperature, acid, base, oxidation reagents and light were found to cause its
degradation. Degradation products were determined with the usage of HPLC equipped
with Q-TOF-MS detector. Calculations of pharmacological and toxicological properties
were performed for six identified degradation products. Target prediction algorithm
was applied on the basis of Hyperpolarization-activated cyclic nucleotide-gated cation
channels, as well as more general parameters like logP and aqueous solubility. Ames
test and five cytochromes activities were calculated for toxicity assessment for selected
degradation products. Pharmacological activity of photodegradation product (UV4),
which is known as active metabolite, was qualified and identified. Two other degradation
compounds (Ox1 and N1), which were formed during degradation process, were found
to be pharmacologically active.
Keywords: ivabradine, stress testing, stability, LC-MS/MS, in silico, ADME/Tox calculations
INTRODUCTION
Guidelines for assessing the quality of active pharmaceutical ingredient (API) and medicinal
products has been developed by ICH, FDA, WHO or EMA, which are focused to the greatest extent,
firstly to verify the stability of the API through the establishment of various tests and the way
there are conducted (ICH Q1A, 1993). Secondly, the confirmation of the presence of impurities
is performed (ICH Q3A, 1993). Studies are performed to explore various paths of the potential
degradation of the API, evaluating the rate of changes under the influence of various factors.
For a comprehensive evaluation process associated with the pharmaceutical stability, there is a
need to perform various tests, which results should be the answer whether the drug substance is
stable. The most important for the drug substance are so-called stress tests, which involve overly
intense exposure to factors such as: strong acid, base, hydrogen peroxide, high temperature or light,
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FIGURE 1 | Theoretical metabolites: main (rank 1) – (A–C) and secondary (rank 3 and > 4) – (D–F) generated by the usage of software Toxtree.
in a manner individual to the different drugs (ICH Q1A
(R2), 2003; Waterman and Adami, 2005). When the chemical
stability of APIs is considered, the effects of chemical reactions
of the API are evaluated, mainly: hydrolysis in conditions
of increased humidity, oxidation in the presence of oxygen
or hydrogen peroxide, isomerization, hydration, dimerization,
or decarboxylation. Photostability tests are characterized by
particular specificity and are an integral part of stability tests that
are included in standard, ICH Q1A (1993). It is worth noting that
the concept of photodegradation is related not only to changes
in the structure of the API under the influence of light, but also
to the occurrence of free-radical processes, energy transfer, or
even luminescence, which may lead to unexpected and atypical
results, especially in the solid state (Glass et al., 2004). There
is a special need to recognize all possibilities of degradation of
new pharmaceutical compound especially those, which are not
recognized in Pharmacopeia yet.
Determination of unknown impurities in the new drug
compound is based on the results obtained during various stress
tests, thus during chemical stability evaluation. Identification
of degradation products is primarily concentrated on
establishing its structure, with simultaneous determination
of physicochemical properties, and then toxicity estimation
accordingly to the latest recommendations (Carstensen and
Rhodes, 2000; EMEA, 2004; Olsen and Larew, 2005; Huynh-Ba,
2008). The first ICH regulations regarding the quantitation limit
of impurities in drug, were based solely on a patient daily dose
of API, routes of administration and duration of therapy and
the identification of impurity of concentration below 0.1% was
unrequired (ICH Q3B (R), 2000). In addition, there was also the
lack of awareness of impurities existing in the drug substance
itself, but in the finished product mainly. In 2004 there has been a
noticeable change in the approach to standards and thresholds of
impurities, as a reaction to the proposal developed by the EMEA,
in which necessity for determination of the genotoxic impurities
limits in the API was stated (EMEA, 2004; Modi et al., 2012). It
has been proposed that the lowest possible quantitation limit of
impurities should be enforced in cases of the predicted presence
of a genotoxic substance formed from an API (Dow et al., 2013;
Maggio et al., 2013). The latest guidelines has been developed in
2014 and requirement to use at least two forecasting models of
mutagenicity predicting in silico was established.
According to current recommendations, it is important to
provide a lot of results in the area of stability testing research
in case of newly implemented pharmaceutical compounds as
well as others already known (Jamrógiewicz, 2016). Ivabradine
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FIGURE 2 | Chromatograms obtained by the HPLC separation of
products of (A) acid hydrolysis and (B) alkaline hydrolysis of
ivabradine.
(IVA) is a new drug compound in the treatment of heart
failure patients and the only implemented HCN4 channel
inhibitor. The drug received an expedited review under the
FDA’s priority review program and the approval was based on
results of the shift trial, published in 2010. Locking HCN4
channel results in slower growth of pacemaker current and as
a result reducing the heart rate. Such action is used to treat
angina, especially in patients with intolerance to β-blockers.
IVA is metabolized by cytochrome CYP3A4 and does not
affect metabolism and plasma concentration of other cytochome
inhibitors. Ivabradine is a highly soluble S-enantiomer with
no in vivo conversion. The only known active metabolite is
N-desmethyl ivabradine (DiFrancesco, 2010; EMA, 2015). There
are no officially published impurities for IVA in pharamacopeias.
The only results focused on degradation and in silico studies
have been performed recently (Patel et al., 2015). So that, it is
important to provide an independent point of view and new data.
There are many models and approaches of in silico studies
(Singh et al., 2012, 2013). In this work, Prediction SwissTarget and
ePhysChem tools were applied (Gfeller et al., 2014; ePhysChem,
2015). By using the above-mentioned software, we evaluated
the toxicity of some identified degradation products. They
FIGURE 3 | HPLC chromatogram showing effect on the addition of
different amounts of H2O2 (A) 3%, (B) 7.5%, and (C) 15%.
were defined by physicochemical parameters such as logP and
solubility, which determine the pharmacokinetics. The IVA
impact on cytochrome P450 (a group of enzymes with oxidase
activity responsible among other things for the detoxification
of the body) has also been examined (Danielson, 2002). The
major enzyme from the group of cytochrome P450 isoenzymes
is CYP3A4, responsible for the metabolism of most drugs or
xenobiotics. Drugs can be metabolized by different enzymes
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FIGURE 4 | HPLC chromatogram showing photolytic degradation in
solution (A) for 24 h, (B) 48 h, and (C) in solid for 120 h.
such as CYP2D6, CYP2C9, CYP2C19, and CYP1A2, therefore,
different metabolites are formed, which activity may be similar
to the original drug substance. Sometimes these products cause
toxic effects (Zanger and Schwab, 2013; Patel et al., 2015).
Physicochemical parameters such as logP and solubility of
degradation products are discussed in this work because of
their importance in perspective of pharmacokinetics (Alavijeh
et al., 2005; Bergström, 2005). If the drug is administered
orally, as ivabradine, it is exposed to low pH in the stomach,
which may form chlorides drug substance with altered properties
(Bergström, 2005).
The main object of this work is to conduct a forced
degradation of ivabradine and propose its possible degradation
products. Stress tests were carried out mainly in context of
resistance to the oxidizing agent, light as well as acid and
base hydrolysis. Additionally, the calculated physicochemical,
pharmacological and toxic properties of possible degradation
products were presented.
MATERIALS AND METHODS
Chemicals
The tested ivabradine hydrochloride (purity≥ 99%) bulk powder
was supplied by Watson International Ltd. (Kunshan, China).
Acetonitrile was purchased from Sigma-Aldrich Chemical CO.
(St. Louis, MO, USA), ammonium acetate, hydrochloric acid
and sodium hydroxide all pure p. a. were purchased from
POCH (Gliwice, Poland). 30% Hydrogen peroxide was supplied
by J. T. Baker, (Deventer, The Netherlands). Pure water was
obtained from Direct-Q3 UV-R Ultrapure water purification
system, Merck Millipore (Darmstadt, Germany).
Equipment and Conditions
LC-MS/MS analysis was performed with HPLC Agilent 1100
(AgilentTechnologies, Santa Clara, CA, USA) equipment coupled
with QSTAR XL (AbSciex, Framingham, MA, USA) mass
spectrometer. Electrospray ionization (ESI) was operated in
a positive ion mode in order to obtain soft and efficient
ionization of ivabradine and its degradation products. Kromasil
100 C8 (4.6 mm × 250 mm, 5 µm, AkzoNobel, Amsterdam,
Netherlands) was used in reversed-phase mode with isocratic
elution. Mobile phase composition was 65% of component
A (20 mM ammonium acetate) and 35% of component
B (acetonitrile). Total analysis time was 30 min. Column
temperature throughout the analysis was 25◦C the flow rate
of the mobile phase was 1 ml/min and the injection volume
was 20 µl. The high resolution Q-TOF mass spectrometer was
operated in SCAN mode to obtain mass spectrum in the mass
range 220–1000 m/z. MS/MS mass spectra were obtained by
collision-induced dissociation of selected parent ions in Product
Ion mode of mass spectrometer. Degradation studies were
carried out in Thermostat CC2-K6 made by Huber company
(Offenburg, Germany), photo stability studies were performed in
a photostability Suntest + Atlas chamber (Accelerated Tabletop
TABLE 1 | Degradation products of all tested samples.
Sample Degradation products Ivabradine [min]
Acid decomposition H1, H2, H3 12.40
Alkaline decomposition N1 12.20
Oxidation (3% H2O2) Ox1, Ox2, Ox3, Ox4, Ox5 –
Oxidation (7.5% H2O2) Ox1, Ox2, Ox4, Ox5 –
Oxidation (15% H2O2) Ox1, Ox2, Ox5 –
Photolysis (24 h) Ox1, UV, UV2, Ox4, UV3, UV4, 11.60
Photolysis (48 h) Ox1, UV2 –
Photolysis (powder 120 h) – 11.64
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FIGURE 5 | Proposed structure and MS/MS fragmentation pattern of H1. (A) MS spectrum and (B) MS/MS spectrum of [M+H]+ ion at 505.31 m/z.
FIGURE 6 | Proposed structure and MS/MS fragmentation pattern of H2. (A) MS spectrum and (B) MS/MS spectrum of [M+H]+ ion at 523.26 m/z.
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FIGURE 7 | Proposed structure and MS/MS fragmentation pattern of H3. (A) MS spectrum and (B) MS/MS spectrum of [M+H]+ ion at 505.25 m/z.
FIGURE 8 | Proposed structure and MS/MS fragmentation pattern of N1. (A) MS spectrum and (B) MS/MS spectrum of [M+H]+ ion at 487.29 m/z.
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FIGURE 9 | Proposed structure and MS/MS fragmentation pattern of Ox4. (A) MS spectrum and (B) MS/MS spectrum of [M+H]+ ion at 293.20 m/z.
FIGURE 10 | Proposed structure and MS/MS fragmentation pattern of UV1. (A) MS spectrum and (B) MS/MS spectrum of [M+H]+ ion at 279.17 m/z.
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FIGURE 11 | Proposed structure and MS/MS fragmentation pattern of UV4. (A) MS spectrum and (B) MS/MS spectrum of [M+H]+ ion at 455.26 m/z.
Exposure Systems) with xenon lamp. Shimadzu UV-1800 UV-Vis
spectrophotometer was also used in the studies.
Stress Testing
In order to prepare degradation sample, for each of the samples
1mg of ivabradine were weighed and dissolved in 2 ml of the
appropriate solvent for particular test sample.
Thermal degradation was performed by adding deionized
water and kept for 24 h in 80◦C. To achieve an acid and alkaline
hydrolysis a 2 M HCl solution and 1 M NaOH were added,
respectively, respectively and incubated for 24 h in 80◦C. Studies
of possible oxidation products were carried out by adding 3%
H2O2, 7.5% H2O2 and 15% H2O2 and incubated for 24 h in 80◦C.
Photolytic degradation was performed in solution of deionized
water for 24 and 48 h as well as in solid form for 120 h. The
illuminance was set at 500 W/m2.
In Silico Calculations
Ivabradine is metabolized by cytochrome P450. To calculate
the probable metabolites, Toxtree program was used (Toxtree,
2015), applying SMARTCyp method to predict the fragments
in the molecule, which are the most susceptible to activity of
cytochrome P450.
For the calculation of toxicity (CYP3A4, CYP2D6, CYP2C9,
CYP2C19, and CYP1A2), logP, solubility and Ames test,
ePhysChem (2015) was used, while the prediction of degradation
compounds on potassium/sodium hyper polarization activated
cyclic nucleotide-gated channel 4 (HCN4) were counted using
SwissTargetPrediction (Gfeller et al., 2014). Calculations were
made for IVA and compounds N1, Ox1, Ox4, Ox5, UV1,
and UV2.
RESULTS AND DISCUSSION
Metabolism/Degradation Products
Prediction
Cytochrome P450 is an enzyme, which demonstrates a
monooxygenase activity (Zanger and Schwab, 2013). In
the absence of these enzymes, but with an appropriate
amount of supplied energy as heat, redox potential, a strong
electrolyte, or UV radiation, reactions can occur in vitro
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TABLE 2 | Comparison of structural formulas, chemical formulas, retention times, molecular ions, as well as the fragment ions of the products obtained
in the experiment.
No Structural
formula
Chemical formula Retention time
[min]
[M+H]+ Fragment ionsa
Hydrolysis
H1 C27H40ClN2O7 HCl – 5.28 505 151, 177, 206,
223, 266, 280
H2 C27H39ClN2O6 HCl – 6.92 523 177, 206, 213,
223, 280, 284
H3 C27H37ClN2O5 HCl – 9.45 505 206, 262
N1 C27H38N2O6 NaOH – 8.11 487 177, 280
Oxidation
Ox1 C15H21N2O4 3% H2O2 – 2.40
7.5% H2O2 – 2.40
15% H2O2 – 2.40
UV 24 h – 2.40 UV
48 h – 2.40
294 175, 191, 206
Ox2 Unknown 3% H2O2 – 4.48
7.5% H2O2 – 4.47
15% H2O2 – 4.49
Inconclusive
Ox3 C27H34N2O6 3% H2O2 – 5.72 471 177, 192, 206, 248
Ox4 C16H24N2O3 3% H2O2 – 6.37
7.5% H2O2 – 6.29
UV 24 h – 6.82
293 175, 206, 262
Ox5 C27H36N2O6 3% H2O2 – 7.75
7.5% H2O2 – 7.68
15% H2O2 – 7.76
485 177, 206, 262
Photolysis
xUV1 C15H22N2O3 UV 24 h – 4.5 279 175, 191, 206
UV2 C16H24N2O4 UV 24 h – 5.56 UV
48 h – 5.58
309 204, 260, 278
UV3 C27H36N2O6 UV 24 h – 7.94 485 146, 177, 204, 278
UV4 C26H34N2O5 UV 24 h – 11.6 455 151, 177, 206, 262
to form the same or similar degradation products. Using
the structure of the molecule and the Toxtree software
(Toxtree, 2015), theoretical metabolites which may be
produced by the action of cytochrome P450 were calculated
(Figure 1).
These theoretical degradation products formed by the
N-demethylation (Figures 1A–E) and N-oxidation (Figure 1F)
are presented in Figure 1.
Chromatogram Evaluation
Ivabradine was tested with the addition of HCl and NaOH
(Figures 2A,B), wherein the concentration of used HCl
was greater than the concentration of used NaOH. On the
chromatogram obtained from a sample after acidic hydrolysis
reaction of IVA (Figure 2A) a satisfactory separation of
ivabradine and the degradation products is observed. Only
compound H2 was not separated from other neighboring
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TABLE 3 | Measured and calculated mass of molecular ion and
fragmentation ion of degradation products, with calculated mass error.
Monoisotopic mass Measured Theoretical Mass error in m/z
IVA [M+H]+ 469.2775 469.2697 −0.0078
262.1509 262.1438 −0.0071
177.1053 177.0910 −0.0143
H1 [M+H]+ 505.2908 505.3073 0.0165
280.1543 280.1684 0.0141
223.0965 223.1020 0.0055
177.0901 177.1003 0.0102
151.0754 151.0814 0.0060
H2 [M+H]+ 523.2590 523.2569 0.0021
284.1424 284.1412 0.0012
280.1684 280.1543 0.0141
223.1020 223.0965 0.0055
213.0758 213.0677 0.0081
177.1053 177.0901 0.0152
151.0814 151.0754 0.0060
H3 [M+H]+ 505.2482 505.2464 0.0018
262.1631 262.1438 0.0193
N1 [M+H]+ 487.2875 487.2803 −0.0072
280.1684 280.1543 −0.0141
177.1003 177.0901 −0.0102
Ox1 [M+H]+ 294.1384 294.1580 0.0196
Ox3 [M+H]+ 471.2718 471.2490 −0.0228
248.1322 248.1281 −0.0041
177.0951 177.0910 −0.0041
Ox 4 [M+H]+ 293.2008 293.1860 −0.0148
262.1570 262.1438 −0.0132
Ox5 [M+H]+ 485.2667 485.2646 −0.0021
262.1502 262.1438 −0.0064
177.0901 177.0910 0.0009
UV1 [M+H]+ 279.1682 279.1703 0.0021
UV2 [M+H]+ 309.1932 309.1809 −0.0123
278.1543 278.1387 −0.0156
UV3 [M+H]+ 485.2814 485.2646 −0.0168
278.1543 278.1387 −0.0156
177.1003 177.0901 −0.0102
UV4 [M+H]+ 455.2592 455.2540 −0.0052
262.1570 262.1438 −0.0132
177.1003 177.0901 −0.0102
151.0860 151.0754 −0.0106
unidentified peak. Separation of the basic hydrolysis degradation
products of ivabradine was achieved with satisfactory result
(Figure 2B).
Complete degradation of IVA was observed in all
samples containing hydrogen peroxide (Figures 3A–C).
Chromatographic separation of degradation products was
achieved. It was noted, that peaks corresponding to the products
Ox5 and Ox4 are smaller in case the higher concentration of
hydrogen peroxide is used in respective samples.
During 24 h photodegradation of IVA, six degradation
products were produced (Figure 4A). 48-h exposure to UV
radiation caused complete decomposition of IVA in solution
(Figure 4B) as well as reduction of the intense of peak
corresponding to the product UV2. Peaks separation in each
UV-tested samples were satisfactory. A lot of photoproducts
in samples and relatively short time of analysis resulted in
insufficient separation of compound UV1. Solid powder form of
ivabradine, exposed to irradiation for 120 h, was proved to be
durable, because any degradation product on the chromatogram
was reveled (Figure 4C).
Determination of degradation products is presented in
Table 1. Differences in retention times and distorted shape
of the peaks corresponding to ivabradine compound tested
in hydrolytic as well as photolytic reaction, is probably
caused by the formation of enantiomers during degradation
processes.
Degradation Product Identification
Using the above described apparatus and conditions, MS/MS
analyses were performed for all chromatographic peaks
(Francois-Bouchard et al., 2000; Lu et al., 2012).
The resulting MS/MS spectra with the proposed
fragmentation patterns are presented in Figures 5–11. The
proposed structures of degradation products together with other
experimental data are presented in Table 2. The accuracy of the
experimental mass degradation products with the theoretical
masses are shown in Table 3.
The ketone group on the benzoazepine ring in compound
H1 has been oxidized to a carboxyl group (Figure 5).
The characteristic peak m/z = 280 on the mass spectrum
corresponding to the open azepine ring near the nitrogen, is
observed for three of the four products of hydrolysis (Figures 5,
6, and 8). Water and HCl near the benzocyclobutene in
compounds H1 and H2 are attached without a covalent bond,
a kind of adducts may be formed. The situation is similar for
the product H3, except that here the ring benzoazepine is intact
(no peak of m/z = 280) and the fragmentation spectrum of
MS/MS proved there is impossible sufficiently formation of the
HCl adduct closely to the molecule (Figure 7). Compound N1, as
another product of ivabradine hydrolysis (Figure 8) differs only
by oxidized carboxyl group on the benzoazepine ring near the
nitrogen, what is observed as opening of the ring.
Due to the high level of noise and discrepancies in the
resulting MS/MS spectrum of compound Ox2, its identification
is impossible, but due to repetition of its occurrence, there is
importance to place attention on that compound in stability
testing of ivabradine.
Limitations of the MS-Q-TOF method used for identification
of degradation products of IVA did not allow for a clear
determination of the attachment site of the hydroxyl group
in compound Ox3, but it is possible the covalent bond forms
between nitrogen atoms in the molecule.
Compounds Ox4 and Ox1 have similar masses (m/z 293.20
and 294.1388, respectively) as well as the fragmentation spectra.
Differences are in the presence of diverse substituents near the
nitrogen atom in the molecule chain, a methyl group in Ox4
(Figure 9), and oxygen in Ox1. Oxygen is coupled to the nitrogen
atom also in case of compound Ox5, where it forms N-oxide
bond.
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TABLE 4 | ADME/Tox calculations for ivabradine and selected degradation products.
[19] [18] [18] [18] [18]
No. [M+H]+ SMILES HCN4
inhibitiona
CYP2D6
inhibition
CYP3A4
inhibition
logPo/w Aqueous
solubility
IVA 468 CN(CCCN1CCc2cc
(c(cc2CC1=O)OC)OC)
CC3Cc4c3cc(c
(c4)OC)OC
0.96b Inhibitor
(57.0%c)
Inhibitor
(74.0%c)
3.18 Log
unit ± 0.38d
3.51 -
log(mol/L)± 0.70d
N1 487 CN(CCCNCCc1cc
(c(cc1CC( = O)O)
OC)OC)CC2Cc3c2cc
(c(c3)OC)OC
0.28b Non-inhibitor
(65.0%c)
Non-inhibitor
(84.0%c)
2.71 Log
unit ± 0.38d
2.39 -
log(mol/L)± 0.70d
Ox1 294 COc1cc2c(cc1OC)
CC( = O)N(CC2)
CCCN[O-]
0.40b Non-inhibitor
(84.0%c)
Non-inhibitor
(86.0%c)
0.57 Log
unit ± 0.74d
0.98 -
log(mol/L)± 0.70d
Ox4 293 CNCCCN1CCc
2cc(c(cc2CC1 = O
)OC)OC
0.82b Non-inhibitor
(69.0%c)
Non-inhibitor
(89.0%c)
1.23 Log
unit ± 0.38d
1.36 -
log(mol/L)± 0.70d
Ox5 485 C[N+](CCCN1CC
c2cc(c(cc2CC1=O)
OC)OC)(CC3Cc4c3cc
(c(c4)OC)OC)[O-]
0.77b Non-inhibitor
(79.0%c)
Inhibitor
(62.0%c)
1.26 Log
unit ± 0.74d
2.39 -
log(mol/L)± 0.70d
UV1 279 COc1cc2c
(cc1OC)CC( = O)
N(CC2)CCCN
0.79b Non-inhibitor
(85.0%c)
Non-inhibitor
(87.0%c)
0.42 Log
unit ± 0.38d
0.9 -
log(mol/L)± 0.70d
UV4 455 COc1cc2c(cc1OC)
CC( = O)N(CC2)
CCCNCC3Cc4c3cc
(c(c4)OC)OC
0.94b Non-inhibitor
(59.0%c)
Inhibitor
(76.0%c)
2.43 Log
unit ± 0.38d
3.03 -
log(mol/L)± 0.70d
aPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4; bprobability; caccuracy; dwithin a confidence interval of 66%.
Compound UV1 (Figure 10) is the degradation product
of the smallest identified molecular weight identified of IVA
(m/z= 279.1725). For compounds UV2 and UV3 it is impossible
to predict its structures, but the data suggest that OH group
is joined in the region of benzoazepine ring. Compound UV4
is varies from ivabradine by the lack of the methyl group on
the nitrogen atom (Figure 11). It is proved, that compound
UV4 is a metabolite of ivabradine produced by cytochrome
P450.
ADME/Tox Screening for Degradation
Products
The calculation of pharmacological and toxicological properties
could be done only for six ivabradine degradation products, since
its chemical structures managed to establish for obtained data.
In other degradation products we proposed the most probable
chemical structures only on the basis of MS/MS analysis.
The pharmacological effect of ivabradine is associated with
blocking of HCN4 channels (Postea and Biel, 2011). Therefore,
in order to make comparative analysis calculations were also
done for ivabradine, even though the drug is introduced into
clinical practice. The in silico calculations made for ivabradine
and selected degradation products demonstrated high probability
of HCN4 channel inhibition for Ox4, Ox5, UV1, and UV4,
which may indicate a certain pharmacological action of these
products (Table 4). For a compound UV4 calculated value
of inhibition is very high (0.94) and only slightly lower than
calculated value for the ivabradine (0.96). It is known that
compound UV4 is a metabolite of ivabradine with proved
ability to inhibit HCN4 channels. Other studies have shown
that it is much weaker inhibitor than ivabradine (DiFrancesco,
2010).
Ivabradine and its degradation products showed no
mutagenicity in the Ames test. It was also shown, that no
inhibition of cytochromes: CYP2C9, CYP2C19, and CYP1A2
(data calculated but not included in Table 4) occurs for all
products of degradation and ivabradine itself. According
to obtained calculations only ivabradine inhibits CYP2D6.
Some authors refer only to the inhibition of CYP3A4 by
IVA (DiFrancesco, 2010; Postea and Biel, 2011), which is
confirmed by our calculations. Compound UV4, which has
lower pharmacological activity than ivabradine, demonstrated
inhibition of cytochrome, the same as compound Ox5.
The values of log P and aqueous solubility, allow to divide
identified degradation products into three groups. Degradation
products of ivabradine - compounds UV4 and N1 have slightly
reduced values of log P and solubility in comparison to IVA.
In the case of degradation products Ox4 and Ox5, significant
reduction of lipophilicity is observed. A strong decrease in
lipophilicity and aqueous solubility occurred in the case of
compounds Ox1 and UV1. Significant reduction of the log
P values can be explained by an aromatic ring being highly
lipophilic moiety.
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CONCLUSION
Stress testing of ivabradine was presented with successful
identification and characterization of its degradation products.
The obtained compounds showed no mutagenic effects in
performed in silico models, in which toxicity and the effect on
cytochromes seems to be small. Another important aspect was,
that their lower water solubility and lipophilicity in comparison
to ivabradine, may influence their bioavailability after oral
administration. Above all, lower pharmacological activity of
degradation products was proven in calculated value of channel
inhibition HCN4. There was also computationally confirmed
pharmacological activity of compound UV4.
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